No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LIXT Lixte Biotechnology
- 2.3901
- -0.1399-5.53%
Close Jul 19 16:00 ET
5.38MMarket Cap-1052P/E (TTM)
2.5294High2.3901Low6.40KVolume2.4901Open2.5300Pre Close15.93KTurnover0.32%Turnover RatioLossP/E (Static)2.25MShares4.420052wk High-14.40P/B4.73MFloat Cap1.580052wk Low--Dividend TTM1.98MShs Float71.9000Historical High--Div YieldTTM5.51%Amplitude1.5800Historical Low2.4900Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Lixte Biotechnology Holdings Inc - Will Provide Its Lead Compound, Lb-100, and Roche Will Provide Atezolizumab for Trial
Express News | Lixte Biotechnology Holdings Announces Collaboration on a New Colon Cancer Clinical Trial
Express News | LIXTE Biotechnology Announces Collaboration With Roche And Netherlands Cancer Institute For Clinical Trial On LB-100's Effectiveness In Enhancing Immune Recognition Of Colon Cancer Cells In MSI Low Metastatic Colon Cancer
Express News | Lixte Biotechnology Holdings to Collaborate With Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
Express News | Lixte Biotechnology: Agreement to Conduct a Phase 1B/2 Clinical Trial of Lb-100, Combined With Atezolizumab for Patients With Metastatic Colon Cancer
Express News | Lixte Biotechnology: Got Into Clinical Trial Agreement With Netherlands Cancer Institute
Comments
$Lixte Biotechnology(LIXT.US$
Lixte Biotechnology Holdings to Collaborate With Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
Lixte Biotechnology Holdings to Collaborate With Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
$Lixte Biotechnology(LIXT.US$ this will hit 4.15 by eod....
1
$Lixte Biotechnology(LIXT.US$
How big is the GVHD market?
US$ 2.71 billion
The Graft Versus Host Disease (GVHD) Treatment Market in 2023 is US$ 2.71 billion, and is expected to reach US$ 5.17 billion by 2031 at a CAGR of 8.42%. FutureWise Research published a report that analyzes Graft Versus Host Disease (GVHD) Treatment Market trends to predict the market's growth.Feb 6, 2024
How big is the GVHD market?
US$ 2.71 billion
The Graft Versus Host Disease (GVHD) Treatment Market in 2023 is US$ 2.71 billion, and is expected to reach US$ 5.17 billion by 2031 at a CAGR of 8.42%. FutureWise Research published a report that analyzes Graft Versus Host Disease (GVHD) Treatment Market trends to predict the market's growth.Feb 6, 2024
$Lixte Biotechnology(LIXT.US$ loaded 👀✔️
10
3
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg